Emerging strategies in targeting tumor vascularization include the combination of anti-angiogenic agents with other therapies such as immunotherapy and chemotherapy. This multi-pronged approach aims to tackle the tumor on multiple fronts, reducing the likelihood of resistance and improving overall treatment efficacy. Researchers are also exploring the use of biomarkers to better predict which patients will respond to anti-angiogenic therapy.
